Clavulanate Potassium

CHEMBL1003 Phase 4 承認済み Small molecule

Half-Life

—

Bioavailability

—

Protein Binding

—

Molecular Weight

237.2 g/mol

LogP

—

Phase

4

The potassium salt form of clavulanic acid, a suicide inhibitor of beta-lactamase enzymes that irreversibly binds to these bacterial enzymes and prevents them from destroying beta-lactam antibiotics. It is combined with amoxicillin or ticarcillin to restore efficacy against beta-lactamase-producing resistant organisms. It has little intrinsic antibacterial activity itself.

分子量

237.2500 g/mol

TPSA

89.90 Å²

治療領域

Infectious Disease Bladder Cancer Asthma Chronic Obstructive Pulmonary Disease Chronic Kidney Disease Obesity Lymphoma Tuberculosis Prostate Cancer Leukemia

作用機序

Inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), preventing transpeptidation and cross-linking of peptidoglycan chains. This weakens the bacterial cell wall, leading to osmotic lysis and cell death.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

機序

Inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), preventing transpeptidation and cross-linking of peptidoglycan chains. This weakens the bacterial cell wall, leading to osmotic lysis and cell …

2D構造

SVG PNG

Cite this structure

Embed this structure

SMILES

O=C([O-])[C@H]1/C(=C/CO)O[C@@H]2CC(=O)N21.[K+]

InChI

InChI=1S/C8H9NO5.K/c10-2-1-4-7(8(12)13)9-5(11)3-6(9)14-4;/h1,6-7,10H,2-3H2,(H,12,13);/q;+1/p-1/b4-1-;/t6-,7-;/m1./s1

Molecular Formula

C8H8KNO5

HBD / HBA

1 / 5

回転可能結合数

2

重原子数

15

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

よくある質問

The potassium salt form of clavulanic acid, a suicide inhibitor of beta-lactamase enzymes that irreversibly binds to these bacterial enzymes and prevents them from destroying beta-lactam antibiotics. It is combined with amoxicillin or ticarcillin to restore efficacy against beta-lactamase-producing resistant organisms. It has little intrinsic antibacterial activity itself.

Inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), preventing transpeptidation and cross-linking of peptidoglycan chains. This weakens the bacterial cell wall, leading to osmotic lysis and cell death.

Yes, Clavulanate Potassium is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1003. Open-access bioactivity database.
PubChem — National Center for Biotechnology Information (NCBI). CID 23665591. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

PillFYI

患者向けのわかりやすい情報をお探しですか？

Clavulanate Potassium PillFYIで

構造

クイックデータ

分子式: C8H8KNO5
同義語: 14

外部リンク

Cite

BibTeX, APA, MLA, Chicago, IEEE, Harvard

医学的免責事項

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.